Astellas Advances Antibody R&D Agenda With Agensys Purchase Worth Up To $537 Million

Astellas has agreed to buy Agensys, a privately held U.S. biotech with a portfolio of novel cancer targets and monoclonal antibodies to match, in a deal worth up to $537 million, the firms announced Nov. 27